4(5)-acetyl-2-(2,2-dimethylpropyl)-1H-imidazole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4(5)-acetyl-2-(2,2-dimethylpropyl)-1H-imidazole
• 英文别名: 1-(2-tert-butyl-1H-imidazol-5-yl)ethanone
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: UQDJKZBQJNZQID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,2-二甲基-N-(5-甲基-4-异恶唑基)丙酰胺 在 sodium hydroxide 、 氢气 作用下， 生成 4(5)-acetyl-2-(2,2-dimethylpropyl)-1H-imidazole
  参考文献：
  名称：

  A general synthesis of 4(5)-acylimidazoles from 4-acylaminoisoxazoles.

  摘要：

  DOI：

  10.1016/s0040-4039(00)98654-4

文献信息

• PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140045789A1

  公开（公告）日：2014-02-13

  The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I wherein J, X, Z, and R 2 are as defined herein. Such compounds are useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.

  本发明涉及一种用于制备公式I的杂环衍生物的方法，其中J、X、Z和R2如本文所定义。这些化合物可用作蛋白酪氨酸激酶抑制剂，更具体地说是c-fms激酶的抑制剂。
• INHIBITORS OF C-FMS KINASE
  申请人：ILLIG Carl R.

  公开号：US20140148448A1

  公开（公告）日：2014-05-29

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及一种式子为I的化合物：其中Z，X，J，R2和W如规范中所述，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I化合物的方法，用于治疗自身免疫性疾病和有炎症成分的疾病；治疗来自卵巢癌，子宫癌，乳腺癌，结肠癌，胃癌，毛细胞白血病和非小细胞肺癌的转移；并用于治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛；以及骨质疏松症，帕吉特病和其他骨吸收介导的疾病，包括关节炎，假体失效，骨溶性肉瘤，骨髓瘤和肿瘤转移到骨骼。
• A general synthesis of 4(5)-acylimidazoles from 4-acylaminoisoxazoles.
  作者：Lawrence A. Reiter

  DOI：10.1016/s0040-4039(00)98654-4

  日期：1985.1
• REITER, L., TETRAHEDRON LETT., 1985, 26, N 29, 3423-3426
  作者：REITER, L.

  DOI：——

  日期：——
• REITER L. A., J. ORG. CHEM., 52,(1987) N 13, 2714-2726
  作者：REITER L. A.

  DOI：——

  日期：——